Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

LIVER

From NAFLD to MAFLD: when pathophysiology succeeds

Nature Reviews Gastroenterology & Hepatology volume 17, pages 387–388 (2020)Cite this article

Subjects

Two new position papers convincingly propose that nonalcoholic fatty liver disease needs a new name — metabolic associated fatty liver disease (MAFLD). A new name for this disease affecting nearly one billion people globally is overdue, as knowledge gained from the past decades has assuringly demonstrated that MAFLD is a purely metabolic disorder.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: MAFLD: an ‘old’ new disease.

References

  1. Ludwig, J., Viggiano, T. R., McGill, D. B. & Oh, B. J. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin. Proc. 55, 434–438 (1980).

    CAS  PubMed  Google Scholar 

  2. Fleming, K. A. et al. Mallory bodies in alcoholic and non-alcoholic liver disease contain a common antigenic determinant. Gut 22, 341–344 (1981).

    Article  CAS  Google Scholar 

  3. Beringer, A. & Thaler, H. Relationships between diabetes mellitus and fatty liver [German]. Dtsch. Med. Wochenschr. 95, 836–838 (1970).

    Article  CAS  Google Scholar 

  4. Day, C. P. & James, O. F. Steatohepatitis: a tale of two “hits”? Gastroenterology 114, 842–845 (1998).

    Article  CAS  Google Scholar 

  5. Marchesini, G. et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am. J. Med. 107, 450–455 (1999).

    Article  CAS  Google Scholar 

  6. Marchesini, G. et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 50, 1844–1850 (2001).

    Article  CAS  Google Scholar 

  7. Eslam, M. et al. A new definition for metabolic associated fatty liver disease: an international expert consensus statement. J. Hepatol. https://doi.org/10.1016/j.jhep.2020.03.039 (2020).

    Article  PubMed  Google Scholar 

  8. Eslam, M., Sanyal, A. J. & George, J. International Consensus Panel MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology https://doi.org/10.1053/j.gastro.2019.11.312 (2020).

    Article  PubMed  Google Scholar 

  9. Tilg, H., Zmora, N., Adolph, T. E. & Elinav, E. The intestinal microbiota fuelling metabolic inflammation. Nat. Rev. Immunol. 20, 40–54 (2020).

    Article  CAS  Google Scholar 

  10. Angulo, P. et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver dmetaisease. Gastroenterology 149, 389–397 (2015).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology & Metabolism, Medical University Innsbruck, Innsbruck, Austria

    Herbert Tilg & Maria Effenberger

Authors
  1. Herbert Tilg
    View author publications

    Search author on:PubMed Google Scholar

  2. Maria Effenberger
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to Herbert Tilg.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tilg, H., Effenberger, M. From NAFLD to MAFLD: when pathophysiology succeeds. Nat Rev Gastroenterol Hepatol 17, 387–388 (2020). https://doi.org/10.1038/s41575-020-0316-6

Download citation

  • Accepted:

  • Published:

  • Version of record:

  • Issue date:

  • DOI: https://doi.org/10.1038/s41575-020-0316-6

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing